Our immune therapy portfolio* is designed to recognize and kill highly multiple tumor targets. With more than 20 years of developing different immune therapies to treat blood cancers and solid tumors, GIMI has a broad and extensive portfolio of antigen targets for CAR-T therapy, Engineered Immune Effector Cells (EIE) therapy, and Dendritic Cells (DC) vaccines.
In clinical studies, our immune therapy products have shown to be safe, contributing to durable anti-tumor responses.
Our portfolio immune therapy has been used to treat over 1000 patients in different clinical trials by our collaborators at the China Hospitals in both blood malignancies and solid tumors.
Several clinical studies are ongoing and planned with our different portfolio immune strategies.
Developing innovative gene and immunological therapies for blood and solid tumor cancers, autoimmune and genetic diseases, and infectious diseases, GIMI has positioned itself in a broad frontline against genetic and autoimmune diseases, infections and cancer.
Based on positive results of the immunological products in various blood and solid tumor cancers, we are now pursuing acute myeloid leukemia as our lead indication with the goal of broadening patient treatment options. We are currently enrolling patients in the safety lead-in portion of our multicenter randomized Phase 2 AML study. See clinical trials**.
case12# The first South America B-Acute Lymphoblastic Leukemia (B-ALL) boy came to China for CART therapy…Cancer History: First diagnosis of cancer: 12/2018 Primary disease: B-ALL
Case10# The First Japanese CART Experience with 4SCART Therapy4 cases of pediatric acute lymphoblastic leukemia with central nervous system
Case9# The PR patient of mucosa-associated lymphoid tissue lymphoma for many yearsA 75 year-old woman sufferred with mucosa-associated lymphoid tissue lymphoma (MALT) for many years
Case8#The CR patient of high burden refractory Burkitt lymphomaA 34 year-old man with high burden refractory Burkitt’s lymphoma
Case13# Long term remission in a 2-year-old patient with refractory/recurrent rhabdomyosarcomaFirst diagnosis of cancer: 09/2013 Rhabdomyosarcoma (RMS) IIIa, cT2aN0M0
case11# The world first successful lentiviral gene therapy treating CGDA 2-month-old boy with X-CGD
Case5# The PR patient of suffering from glioblastoma with relapseA 43 year-old male suffering from glioblastoma with relapse
Case1# 9 year CR of cervical cancer patientA 34 year-old woman with cervical cancer and right pelvic pain
Our immune therapies portfolio are currently being evaluated in several clinical studies across blood derived malignancies and solid tumors.
GIMI provides innovative, personalized medical care to patients from around the world. We have an extensive collaborators hospitals in China dedicated to providing advanced and compassionate medicine for everyone.
We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.